1. Home
  2. CYTH vs RAND Comparison

CYTH vs RAND Comparison

Compare CYTH & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTH
  • RAND
  • Stock Information
  • Founded
  • CYTH 1990
  • RAND 1969
  • Country
  • CYTH United States
  • RAND United States
  • Employees
  • CYTH N/A
  • RAND N/A
  • Industry
  • CYTH Biotechnology: Pharmaceutical Preparations
  • RAND Finance: Consumer Services
  • Sector
  • CYTH Health Care
  • RAND Finance
  • Exchange
  • CYTH Nasdaq
  • RAND Nasdaq
  • Market Cap
  • CYTH 35.5M
  • RAND 38.1M
  • IPO Year
  • CYTH N/A
  • RAND N/A
  • Fundamental
  • Price
  • CYTH $1.26
  • RAND $16.85
  • Analyst Decision
  • CYTH Strong Buy
  • RAND
  • Analyst Count
  • CYTH 3
  • RAND 0
  • Target Price
  • CYTH $3.20
  • RAND N/A
  • AVG Volume (30 Days)
  • CYTH 25.0K
  • RAND 2.4K
  • Earning Date
  • CYTH 08-12-2024
  • RAND 08-02-2024
  • Dividend Yield
  • CYTH N/A
  • RAND 6.90%
  • EPS Growth
  • CYTH N/A
  • RAND 232.84
  • EPS
  • CYTH N/A
  • RAND 2.23
  • Revenue
  • CYTH $1,126,444.00
  • RAND $7,553,884.00
  • Revenue This Year
  • CYTH $28.30
  • RAND N/A
  • Revenue Next Year
  • CYTH $14.19
  • RAND N/A
  • P/E Ratio
  • CYTH N/A
  • RAND $7.33
  • Revenue Growth
  • CYTH N/A
  • RAND 16.36
  • 52 Week Low
  • CYTH $0.89
  • RAND $12.50
  • 52 Week High
  • CYTH $2.12
  • RAND $19.60
  • Technical
  • Relative Strength Index (RSI)
  • CYTH 48.10
  • RAND 61.49
  • Support Level
  • CYTH $1.13
  • RAND $14.30
  • Resistance Level
  • CYTH $1.40
  • RAND $14.77
  • Average True Range (ATR)
  • CYTH 0.09
  • RAND 0.58
  • MACD
  • CYTH 0.02
  • RAND 0.11
  • Stochastic Oscillator
  • CYTH 48.15
  • RAND 96.93

About CYTH Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.

Share on Social Networks: